Marine Natural Products: A Source of Novel Anticancer Drugs
Open accessThe DOI matches its Crossref record; 215 of the 235 references it cites were found in a registry or an index; 37 of the 152 sources its claims cite were checked for support.
Abstract
Cancer remains one of the most lethal diseases worldwide. There is an urgent need for new drugs with novel modes of action and thus considerable research has been conducted for new anticancer drugs from natural sources, especially plants, microbes and marine organisms. Marine populations represent reservoirs of novel bioactive metabolites with diverse groups of chemical structures. This review highlights the impact of marine organisms, with particular emphasis on marine plants, algae, bacteria, actinomycetes, fungi, sponges and soft corals. Anti-cancer effects of marine natural products in in vitro and in vivo studies were first introduced; their activity in the prevention of tumor formation and the related compound-induced apoptosis and cytotoxicities were tackled. The possible molecular mechanisms behind the biological effects are also presented. The review highlights the diversity of marine organisms, novel chemical structures, and chemical property space. Finally, therapeutic strategies and the present use of marine-derived components, its future direction and limitations are discussed.
Overview
CoChat Summary
TL;DR
This review summarizes marine natural products as sources of novel anticancer drugs, covering marine plants, algae, bacteria, actinomycetes, fungi, sponges, and soft corals. It highlights cytotoxic and mechanistic findings, clinical candidates, and chemical property-space diversity, while noting that many marine compounds remain preclinical and the deep sea is largely unexplored.
Key findings
- Marine-derived compounds show anticancer activity across many tumor cell lines: cryptophycin 1 had IC50 = 0.005 and 0.003 ng/mL against KB and LOVO cells; coibamide A had LC50 < 23 nM against NCIH460 lung and mouse neuro-2a cells; salinosporamide A had IC50 = 0.13, 0.28, 7.5, and 35.0 µM against A-549, HL-60, BEL-7402, and P388 cells, respectively.
- The review reports 13 natural products isolated from marine organisms being tested in different phases of clinical trials; examples include bryostatin 1 in phase II, ET-743 in phase I, and dolastatin 10 in phase II. Marine-based drugs cited as used against leukemia, metastatic breast cancer, soft tissue sarcoma, and ovarian cancer include cytarabine, eribulin mesylate, brentuximab vedotin, and trabectidine.
- Marine biodiversity is described as vast: oceans cover over 70% of the earth, nearly 250,000 marine species are described, 99% of all bacteria cannot be cultured, and there are more than 22,000 known microbial secondary metabolites, 70% produced by actinomycetes, 20% by fungi, 7% by Bacillus spp., and 1–2% by other bacteria.
- ChemGPS-NP analysis using eight principal components based on 35 molecular descriptors showed that the reviewed marine compounds did not form tight clusters, indicating chemical diversity within classes such as marine peptides.
Methods
- Narrative review of marine natural products with anticancer activity, emphasizing marine plants, algae, bacteria, actinomycetes, fungi, sponges, and soft corals, and covering in vitro, in vivo, and clinical trial reports.
- For chemical property space, chemical structures were converted to SMILES using Chemsketch and submitted to ChemGPS-NPweb; eight principal component values were obtained from 35 molecular descriptors per compound, and PC1, PC2, and PC3 were plotted in three dimensions.
- Main analysis is qualitative synthesis of reported cytotoxic activities, mechanisms, and clinical status; no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described.
Limitations
- Stated in the paper: sampling difficulties and the need for sufficiently large quantities for detailed analyses; less than 5% of the deep sea has been explored and less than 0.01% of the deep-sea floor sampled in detail; preclinical and clinical data for marine natural compound chemoprevention remain scant; NMR is less sensitive than MS and some compound classes cannot be detected by MS; many compounds such as calothrixins A/B, ulithiacyclamide, patellamide, borophycin, and largazole have not yet entered clinical trials; the exact mechanism of sansalvamide A is unknown.
- Evident from the text: as a narrative review, it lacks a systematic search strategy, formal inclusion/exclusion criteria, risk-of-bias assessment, and quantitative pooling, so the findings are illustrative rather than exhaustive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
32 Valid · 3 Not valid · 64 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Advanced technology and extensive research on marine natural products have led to the discovery of a new generation of anticancer drugs currently used in clinical trials [6].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 1. Introduction
What the sources say
- Partly supportedcites [6] Ang, 2000, In vivo antimalarial activity of the beta-carboline alkaloid manzamine A, Antimicrob. Agents Chemother. sourceExperimental — accuracy not yet measured
The Abstract (page not specified) says marine-sponge manzamines had attracted interest as potential anticancer agents and inhibited cancer-cell growth. It does not say that advanced technology produced a new generation of anticancer drugs or that any were in clinical trials; this paper reports antimalarial testing in mice. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Natural bioactive molecules exhibit cytotoxic effects by attacking macromolecules expressed by cancer cells, such as those in oncogenic signal transduction pathways [16].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 1. Introduction
What the sources say
- Supportedcites [16] Nobili, 2009, Natural compounds for cancer treatment and prevention, Pharmacol. Res. source
The Conclusions describe natural compounds with cytotoxic activity that target macromolecules in cancer cells, including compounds targeting oncogenic signal-transduction pathways. The citing sentence paraphrases that distinction. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Over the past 50 years, emerging evidence has shown that many natural products derived from plants and microbes of marine origin (Table 1), exhibit beneficial effects in the prevention and treatment of cancer, i.e., cytarabine, eribulin mesylate, brentuximab vedotin, and trabectidine are marine-based drugs used against leukemia, metastatic breast cancer, soft tissue sarcoma and ovarian cancer [20,”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 2. Nature and Cancer Chemotherapy
What the sources say
- Partly supportedcites [20] Dyshlovoy, S.A., and Honecker, F. (2018). Marine compounds and cancer: 2017 updates. Mar. Drugs, 16. sourceExperimental — accuracy not yet measured
The paper’s main text reports anticancer activity in compounds from marine algae and microbes and identifies four marine-derived drugs approved to treat cancer. It does not establish beneficial effects in cancer prevention, so the prevention portion of the claim is unsupported. (LLM, conf=0.85)
- Not matchedcites [21] (2019, August 17). Drug Bank. Available online: http://www.drugbank.ca.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The bryostatin 1 has recently entered phase II clinical trial against melanoma, non-Hodgkin’s lymphoma, renal cancer and colorectal cancer [58,59,60].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs
What the sources say
- Not checked — no full text of the sourcecites [58] Bourhill, 2017, Enzastaurin: A lesson in drug development, Crit. Rev. Oncol. Hematol. source
- Partly supportedcites [59] Wang, 2013, Marine-derived angiogenesis inhibitors for cancer therapy, Mar. Drugs sourceExperimental — accuracy not yet measured
Section 4.1 reports phase I and II bryostatin-1 trials involving all four named cancers, and the References list phase II studies for each, including colorectal cancer (ref. 132). But the paper says more than 80 phase I and II trials had been conducted since 1993; it does not support the claim that bryostatin-1 had recently entered phase II trials. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [60] Ritchie, 2015, Cancer research UK centre for drug development: Translating 21st-century science into the cancer medicines of tomorrow, Drug Discov. Today source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Based on modern research, cultured benthic cyanobacteria from temperate marine environments provide a promising, under-exploited source for novel drugs against leukemia [107].”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs > 5.1. Marine Plants
What the sources say
- Could not verifycites [107] Peng, 2010, Structure and absolute configuration of karlotoxin-2, an ichthyotoxin from the marine dinoflagellate Karlodinium veneficum, J. Am. Chem. Soc. sourceExperimental — accuracy not yet measured
The Abstract describes karlotoxin-2 from the marine dinoflagellate Karlodinium veneficum and its toxicity to fish. Searches for benthic cyanobacteria and leukemia found no passage addressing their potential as a source of leukemia drugs. (LLM, conf=0.77)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Could not verify
69 more claims · 15 with their cited sources checked
Create a free account to see all 110 claims and to verify the 12 references still open.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 18
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs > 5.1. Marine Plants
“against KB cells and 5 µg/mL against LOVO cells (colon cancer)”
§ Marine Natural Products: A Source of Novel Anticancer Drugs > 5. From Marine Organisms to Anticancer Drugs > 5.1. Marine Plants
“against human epidermoid carcinoma (LOVO) and human colorectal adenocarcinoma (KB) cell lines”
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 2×
“In 2018, approximately 18 million new cases of cancer reported globally, resulting in approximately 10 million deaths [1].”
BackgroundCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Prokaryotes: The unseen majority
Whitman, W. B., Coleman, D. C., & Wiebe, W. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6578 · Cited by 4,871
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687 · cited 2×
“Approximately 80% of the approved chemotherapeutic drugs [13], and more than half of all drugs are based on bioactive natural products [14].”
BackgroundBioactive Microbial Metabolites: A Personal View
Bérdy, J. (2005) · The Journal of Antibiotics · doi:10.1038/ja.2005.1 · Cited by 3,170 · cited 1×
“Of these actinomycete-derived compounds, 75% were derived from Streptomyce whereas 25% were derived from rare actinomycetes [125,126].”
BackgroundNatural products as sources of new drugs over the period 1981–2002
Newman, D. J., Cragg, G. M., & Snader, K. M. (2003) · Journal of Natural Products · doi:10.1021/np030096l · Cited by 3,082 · cited 1×
“Approximately 80% of the approved chemotherapeutic drugs [13], and more than half of all drugs are based on bioactive natural products [14].”
BackgroundMedicinal plants: Traditions of yesterday and drugs of tomorrow
Gurib-Fakim, A. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.008 · Cited by 2,391 · cited 1×
“The incidence of cancer continues to increase due to environmental changes and life style modernization [3].”
BackgroundShahidi, F., Janitha, P. K., & Wanasundara, P. D. (1992) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408399209527581 · Cited by 2,238
Research works printed but not linked: 7
- Whitman, 1998, The unseen majority, Proc. Natl. Acad. Sci. USA, 74, 5088
- Reyes, 2002, The marine pharmacy: New antitumoral compounds from the sea, Pharm. News, 9, 495
- Laatsch, H. (2011). AntiBase 2011: The Natural Compound Identifier, Wiley-Vch.
- Harmon, 2000, Ecteinascidin-743 (et-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: Results from phase Ii trials, Ann. Oncol., 11, 126
- Lavakumar, 2012, Anticancer and antioxidant effect of Acanthophora spicifera against EAC induced carcinoma in mice, J. Pharm. Res., 5, 1503
- Suja, 2014, Anticancer activity of compounds isolated from marine endophytic fungus Aspergillus terreus, World J. Pharm. Pharm. Sci., 3, 661
- Devi, 2015, Molecular modeling, quantitative structure activity relationship and pharmacophore studies on antiǧviral, antiǧmalarial and antiǧinflammatory bioactive compounds from marine sources, Asian J. Pharm. Clin. Res., 8, 36
Cited by
Items 201–300 of 551
Shin, H. J., Ánh, C. V., Cho, D.-Y., et al. (2021) · Molecules · doi:10.3390/molecules26040836 · Cited by 12
“Over the past few decades, emerging evidence has shown that many marine natural products, such as cytarabine, eribulin mesylate, brentuximab vedotin, and trabectidine exhibit beneficial effects in the prevention and treatment of cancer [22].”
BackgroundJalili, C., Abbasi, A., Rahmani-Kukia, N., Andarzi, S., Kakebaraie, S., & Nasta, T. Z. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116316 · Cited by 15
Nova, P., Cunha, S. A., Costa-Pinto, A. R., & Gomes, A. (2024) · Marine Drugs · doi:10.3390/md22070319 · Cited by 13
Surwase, A. J., & Thakur, N. L. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108449 · Cited by 14
Yang, S., Liu, Y., Xiao, Z., et al. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103187 · Cited by 12
Bioactive Compounds with Antiglioma Activity from Marine Species
Khotimchenko, R., Bryukhovetskiy, I., Khotimchenko, M., & Khotimchenko, Y. S. (2021) · Biomedicines · doi:10.3390/biomedicines9080886 · Cited by 13
de la Fuente, B., Berrada, H., & Barba, F. J. (2022) · Current Opinion in Food Science · doi:10.1016/j.cofs.2022.01.001 · Cited by 13
Fares, N., & Luzzatto‐Knaan, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23148048 · Cited by 13
“In addition, several MNPs are currently being evaluated in different phases of human clinical trials [31,32].”
BackgroundBreaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology
Wang, H., He, Y., Jian, M., Fu, X., Cheng, Y., He, Y., Fang, J., Li, L., & Zhang, D. (2022) · Molecules · doi:10.3390/molecules27217480 · Cited by 12
The Antiangiogenic and Antitumor Effects of Scoparasin B in Non-Small-Cell Lung Cancer
Lin, K., Huang, L., Zhang, Y., et al. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00979 · Cited by 12
Yang, K., Lin, Y., Wang, S.-C., Lee, M.-Y., Tang, J., Chang, F., Chuang, Y.-T., Sheu, J., & Chang, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100994 · Cited by 12
Self-citationCallaghan, B., Twigg, M. S., Baccile, N., et al. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12115-6 · Cited by 12
Toward “E‐Ring‐Free” Lamellarin Analogues: Synthesis and Preliminary Biological Evaluation
Rusanov, D. A., Alfadul, S. M., Portnyagina, E. Y., Silyanova, E. A., Kuznetsov, N. A., Podpovetny, K. E., Samet, A. V., Semenov, V. V., & Babak, M. V. (2023) · ChemBioChem · doi:10.1002/cbic.202300161 · Cited by 12
Anti-cancer properties of Sansalvamide A, its derivatives, and analogs: an updated review
Chagaleti, B. K., Baby, K., Peña‐Corona, S. I., Leyva‐Gómez, G., Sindhoor, S. M., Naveen, N. R., Jose, J., Aldahish, A. A., Sharifi‐Rad, J., & Călina, D. C. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03129-0 · Cited by 11
“Marine fungi, particularly those associated with sediment or marine organisms, are notable for producing diverse and structurally unique bioactive compounds like Sansalavamide A (Belofsky et al. 1999a; Khalifa et al. 2019).”
Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
Debnath, A., Mazumder, R., Singh, A. K., & Singh, R. K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313830 · Cited by 13
“Many marine-derived compounds exhibit potent anti-proliferative effects, making them promising candidates for cancer therapy, including as potential CDK4/6 inhibitors [23].”
Wu, C., Li, Y., Hung, T., Chang, Y., Huang, Y.-H., & Wu, Y. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00584 · Cited by 11
Potential inhibitors for SARS-CoV-2 Mpro from marine compounds
Tâm, N. M., Quân, P. M., Nguyen, H. T., Hong, N. D., Hien, N. K., Quang, D. T., Phùng, H. T. T., & Ngô, S. T. (2021) · RSC Advances · doi:10.1039/d1ra03852d · Cited by 11
Chen, D.-L., Chen, M.-Y., Hou, Y. J., et al. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00849 · Cited by 11
Salazar-Mendoza, J., León-Deniz, L. V., Mirón‐López, G., Moo-Puc, R. E., Chalé-Dzul, J. B., & Mena‐Rejón, G. J. (2020) · Natural Product Research · doi:10.1080/14786419.2020.1753739 · Cited by 10
Cytotoxicity and apoptosis induction of the marine Conus flavidus venom in HepG2 cancer cell line
Magdy, N. A., Nafie, M. S., El-Naggar, M. S., et al. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2125075 · Cited by 10
Alves, C., Silva, J., Pintéus, S., Guedes, R. A., Guedes, R. C., Alvariño, R., Freitas, R., Goettert, M. I., Gaspar, H., Alfonso, A., et al. (2022) · Marine Drugs · doi:10.3390/md20100652 · Cited by 12
“Among MNPs, polyphenols, polysaccharides, alkaloids, peptides, and terpenoids have demonstrated great anticancer activities in in vitro, preclinical, and clinical studies [7,10].”
BackgroundGuo, Y.-S., Zuo, T., Chen, A., Wang, Z., Jin, H., Wei, F., Li, P., & Ma, S. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00776-y · Cited by 15
“Some studies have found that MTCMs have pharmacological effects such as anti-viral, anti-tumor, anti-inflammatory, and treatment of cardiovascular and neurological diseases [5].”
BackgroundRecent Updates on the Antimicrobial Compounds from Marine‐Derived Penicillium fungi
Li, H., Fu, Y., Song, F., & Xu, X. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301278 · Cited by 12
Anticancer diterpenes of African natural products: Mechanistic pathways and preclinical developments
Bangay, G., Brauning, F. Z., Rosatella, A. A., Díaz-Lanza, A. M., Domínguez-Martín, E. M., Gonçalves, B. M. F., Hussein, A. A., Efferth, T., & Rijo, P. M. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155634 · Cited by 10
Ravichandiran, P., Martyna, A., Kochanowicz, E., Maroli, N., Kubiński, K., Masłyk, M., Boguszewska‐Czubara, A., & Ramesh, T. (2024) · ChemMedChem · doi:10.1002/cmdc.202400495 · Cited by 11
Pradhan, B., & Ki, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136593 · Cited by 14
Qiu, Y., Xu, J., Liao, W., Yang, S., Wen, Y., Farag, M. A., Zheng, L., & Zhao, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142252 · Cited by 12
Self-citationZhang, S., Wang, H., Sai, C., Wang, Y., Cheng, Z., & Zhang, Z. (2025) · Marine Drugs · doi:10.3390/md23050197 · Cited by 13
Eltamany, E. E., Abdelmohsen, U. R., Hal, D. M., Ibrahim, A. K., Hassanean, H. A.-H., Abdelhameed, R. F. A., Temraz, T. A., Hajjar, D., Makki, A. A., Hendawy, O. M., et al. (2021) · Molecules · doi:10.3390/molecules26061555 · Cited by 12
“organisms are regarded as a huge reservoir of novel bioactive metabolites [2,3].”
BackgroundMalla, R. R., Farran, B., & Nagaraju, G. P. (2021) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v12.i2.15 · Cited by 10
Alves, C., Silva, J., Afonso, M. B., Guedes, R. A., Guedes, R. C., Alvariño, R., Pintéus, S., Gaspar, H., Goettert, M. I., Alfonso, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112886 · Cited by 11
“Over the last decades, marine organisms have revealed to be a pro-lific source of unusual and distinct chemical structures with great pharmacological potential [23 – 25].”
BackgroundKaluzhnaya, O. V., & Itskovich, V. B. (2022) · Russian Journal of Genetics · doi:10.1134/s1022795422030061 · Cited by 10
Alves, Â. V. F., Melo, C. R., Chagas-Neto, J. L., Amaral, R. G., Ambrósio, S. R., Moreira, M. R., Veneziani, R. C. S., Cardoso, J. C., Severino, P. B., GONDAK, R. D. O., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122497 · Cited by 11
Alsufyani, T. A., Al‐Otaibi, N., Alotaibi, N. J., et al. (2023) · Molecules · doi:10.3390/molecules28104255 · Cited by 10
“It is estimated that Actinomycetes are responsible for the production of 70% of secondary microbial compounds [9], while Bacilli and other bacteria produce around 7% and 1–2%, respectively [10].”
BackgroundKiss, A., Akbari, F. H., Marchev, A. S., Papp, V., & Mirmazloum, I. (2023) · Life · doi:10.3390/life13081623 · Cited by 12
Heteronemin promotes iron-dependent cell death in pancreatic cancer
Kaftan, G., Erdoğan, M. A., El‐Shazly, M., Lu, M., Shih, S., Lin, H., Saso, L., & Armağan, G. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02736-7 · Cited by 14
“Notable among these are compounds like pachymatismin, bryostatins, and heteronemin (Newman and Cragg 2014; Zidane et al. 1996; Khalifa et al. 2019).”
de França, P., Costa, J. H., Fill, T. P., Lancellotti, M., Ruiz, A. L. T. G., & Fantinatti‐Garboggini, F. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03691-w · Cited by 11
“The high level of mortality and the specificity of the treatment leads to the urgent need for novel antiproliferative compounds (Khalifa et al. 2019).”
BackgroundHuang, Y., Yan, H., Zhang, B., Zhu, G., Yu, J., Xiao, X., He, W., Chen, Y., Gao, X., She, Z., et al. (2023) · Marine Drugs · doi:10.3390/md21120600 · Cited by 11
“…to the ecological environment; finally, by studying compound synthesis routes, adjusting fermentation conditions and the activity of key metabolic enzymes, it is possible to obtain more structurally novel compounds, which will be more conducive to improving the utilization of marine resources [41].”
BackgroundAbdelhameed, R. F. A., Eltamany, E. E., Hal, D. M., Ibrahim, A. K., AboulMagd, A. M., Al-Warhi, T. I., Youssif, K. A., El-kader, A. M. A., Hassanean, H. A.-H., Fayez, S., et al. (2020) · Marine Drugs · doi:10.3390/md18080405 · Cited by 10
“Marine organisms can be considered as a great reservoir of new bioactive compounds that can aid in the prevention and treatment of different ailments, including cancer [3].”
BackgroundCRISPR/Cas12a-Mediated Gene Editing in Geodia barretti Sponge Cell Culture
Hesp, K., Flores, J., Alexandru, A.-M., van der Linden, J., Martens, D. E., Wijffels, R. H., & Pomponi, S. A. (2020) · Frontiers in Marine Science · doi:10.3389/fmars.2020.599825 · Cited by 11
“This method has been used to edit genes in mammalian cells (Hur et al., 2016; Liu et al., 2019a), zebrafish (Liu et al., 2019b), mouse embryos (Hur et al., 2016), and plants (Kim et al., 2017).”
MethodGastroprotection against Rat Ulcers by Nephthea Sterol Derivative
Mohamed, T. A., Elshamy, A. I., Ibrahim, M. A. A., Atia, M. A. M., Ahmed, R. F., Ali, S. K., Mahdy, K. A., Alshammari, S. O., Al-Abd, A. M., Moustafa, M., et al. (2021) · Biomolecules · doi:10.3390/biom11081247 · Cited by 13
Self-citationChoi, H. Y., Ahn, J., Kwon, H., Yim, J. H., Lee, D., & Choi, J. (2022) · Marine Drugs · doi:10.3390/md20050275 · Cited by 10
“A wide range of marine natural products have been reported to exert anticancer activities through induction of cytotoxicity and apoptosis [54].”
BackgroundAlshammari, S. O., Aldakhil, T., Alshammari, Q. A., Salehi, D., & Ahmed, A. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03616-y · Cited by 8
Delgado, D. L. C., Caceres, L. L. C., Gómez, S. A. C., & Odio, A. D. (2023) · Veterinary World · doi:10.14202/vetworld.2023.965-976 · Cited by 19
Rentería-Mexia, A. M., Ulloa‐Mercado, G., Gortáres‐Moroyoqui, P., González‐Mercado, A., Sánchez, M., Sineiro, J., & Núñez, M. J. (2022) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.7113 · Cited by 10
Hu, J., Zhang, W., Tan, H., et al. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob00585a · Cited by 9
Multiple Myeloma: Possible Cure from the Sea
Capalbo, A., & Lauritano, C. (2022) · Cancers · doi:10.3390/cancers14122965 · Cited by 11
Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
Trinidad-Calderón, P. A., Varela-Chinchilla, C. D., & García‐Lara, S. (2023) · Molecules · doi:10.3390/molecules28020670 · Cited by 10
“The mechanism of action of depsipeptides in vivo relies on apoptotic, necrotic, or lytic phenomena [20].”
BackgroundNovel marine natural products as effective TRPV1 channel blockers
Ye, W., Lui, S. T., Zhao, Q., Wong, Y. M., Cheng, A., Sung, H. H. Y., Williams, I. D., Qian, P., & Huang, P. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127136 · Cited by 9
Suleiman, S., Fiore, R. D., Cassar, A., Formosa, M. M., Calleja‐Agius, J., & Schembri-Wismayer, P. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110549 · Cited by 12
Cabeza, L., Peña, M., Martínez, R., Mesas, C., Galisteo, M., Perazzoli, G., Prados, J. C., Porres, J. M., & Melguizo, C. (2021) · Biology · doi:10.3390/biology10020134 · Cited by 10
“The PUFA with the highest concentration was 5,8,11,14,17-eicosapentaenoic acid (EPA), which also showed higher levels in Anemonia sulcata W/O its symbiont (35.1% W/O versus 29.7% W).”
InfluentialReptiles as Promising Sources of Medicinal Natural Products for Cancer Therapeutic Drugs
Park, S. Y., Choi, H., & Chung, J. W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040874 · Cited by 9
Mohammadi, M., Zambare, V., Suntres, Z. E., & Christopher, L. P. (2022) · Processes · doi:10.3390/pr10071361 · Cited by 11
“About 60% of all natural compounds are known as pharmaceutical agents [15], with more than half of all approved drugs for cancer treatment originating from natural sources [16].”
BackgroundWang, H.-R., Chen, P., Tang, J., Yen, C.-Y., Su, Y., Huang, M., & Chang, H. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6667355 · Cited by 11
New glucose-6-phosphate dehydrogenase inhibitor from the Red Sea sponge Echinoclathria sp
Abdelhameed, R. F. A., Habib, E. S., Eltahawy, N. A., Hassanean, H. A.-H., Ibrahim, A. K., Fahim, J. R., Sayed, A. M., Hendawy, O. M., Abdelmohsen, U. R., & Ahmed, S. A. (2021) · Tetrahedron Letters · doi:10.1016/j.tetlet.2021.152986 · Cited by 9
Gao, H., Xie, P.-F., Zhang, X., et al. (2021) · Marine Drugs · doi:10.3390/md19080458 · Cited by 9
“Actinobacteria are a unique prokaryote group and a virtually unlimited source due to their extraordinary abilities to deliver a multitude of novel bioactive lead compounds with medical, pharmaceutical, industrial and ecological significance [1,2].”
BackgroundSinularin stabilizes FOXO3 protein to trigger prostate cancer cell intrinsic apoptosis
Meng, X., Wang, K., Ye, S., Chen, J., Chen, Z.-Y., Zhang, Z., Yin, W.-Q., Jia, X.-L., Li, Y., Yu, R., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.116011 · Cited by 9
Anticancer Activity of Sargassum fluitans Extracts in Different Cancer Cells
González-Garrido, J. A., Gómez-García, J. A., Hernández‐Abreu, O., et al. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206282983240215050314 · Cited by 8
Chen, Z., Wu, J., Wang, N., Li, T., Wu, H., Wu, H., & Xiang, W. (2024) · Molecules · doi:10.3390/molecules29194556 · Cited by 9
“This demonstrates the potential of cyanobacteria as a potent source of natural antitumor metabolites when more research is implemented [30–32].”
BackgroundAfkhami, H., Yarahmadi, A., Bostani, S., Yarian, N., Haddad, M. S., Lesani, S. S., Aghaei, S. S., & Zolfaghari, M. R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01590-0 · Cited by 15
Unlocking potent anti-tuberculosis natural products through structure–activity relationship analysis
Abdjul, D. B., Budiyanto, F., Wibowo, J. T., et al. (2025) · Natural Products and Bioprospecting · doi:10.1007/s13659-025-00529-4 · Cited by 8
Cui, X., Zhao, X., Li, J., Li, Z., Ren, X., Zhao, Y., Fu, X., & Li, X. (2021) · Frontiers in Marine Science · doi:10.3389/fmars.2021.774927 · Cited by 8
“Ko et al. (2016) identified a goose-type lysozyme (ShLysG) from Hippocampus abdominalis Lesson that had a certain inhibitory effect against gram-positive/negative bacteria and a potential immune-protecting effect against pathogens.”
Background(2022) · Jordan Journal of Biological Sciences · doi:10.54319/jjbs/150103 · Cited by 8
Chen, J., Guo, X., Li, D., Tang, H., Gao, J., Yu, W., Zhu, X., Sun, Z., Huang, Z., & Chen, L. (2023) · Metallomics · doi:10.1093/mtomcs/mfad035 · Cited by 9
Self-citationSun, T.-T., Zhu, H., & Cao, F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201026150105 · Cited by 8
Abdelkarem, F. M., Desoky, E.-E. K., Nafady, A. M., et al. (2020) · Natural Product Research · doi:10.1080/14786419.2020.1855162 · Cited by 8
“However, compounds isolated from natural source either from marine organisms or terrestrial origin considered to be one of the promising way for discovery of drug leads which can subject to further modification for treatment of cancer (Demain and Vaishnav 2011; Khalifa et al. 2019).”
BackgroundBioprospecting Antiproliferative Marine Microbiota From Submarine Volcano Tagoro
García-Davis, S., Reyes, C. P., Lagunes, I., et al. (2021) · Frontiers in Marine Science · doi:10.3389/fmars.2021.687701 · Cited by 8
Cytotoxic Activity of Isoniazid Derivative in Human Breast Cancer Cells
Barathan, M., Zulpa, A. K., Vellasamy, K. M., Mariappan, V., Shivashekaregowda, N. K. H., Ibrahim, Z. A., & Vadivelu, J. (2021) · In Vivo · doi:10.21873/invivo.12551 · Cited by 8
Deng, N., Huang, H., Hu, Y., et al. (2022) · Antonie van Leeuwenhoek · doi:10.1007/s10482-022-01773-1 · Cited by 8
“Marine natural products are relatively efficient in the discovery of drug leads (Pereira 2019; Khalifa 2019), including the anti-cancer drugs trabectedin (discovered from a marine tunicate Ecteinascidia turbinata), eribulin mesylate (synthetic mimic to halichondrin B, which was isolated from a marine sponge Halichondr…”
BackgroundNoufal, Z. M., Sivaperumal, P., & Elumalai, P. (2022) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_331_22 · Cited by 15
“[52] There are previous studies indicating that the marine actinobacterium of Streptomyces species has anticancer potential.[53]”
ResultAlbofungin and chloroalbofungin: antibiotic crystals with 2D but not 3D isostructurality
Ye, W., She, W., Sung, H. H. Y., Qian, P., & Williams, I. D. (2020) · Acta Crystallographica Section C Structural Chemistry · doi:10.1107/s2053229620015041 · Cited by 8
Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer
Sajeev, A., Aswani, B. S., Alqahtani, M. S., Abbas, M. A. E., Sethi, G., & Kunnumakkara, A. B. (2025) · Cancers · doi:10.3390/cancers17142328 · Cited by 13
“Natural compounds derived from plants, microorganisms, and marine organisms, because of their biological properties and relatively low toxicity profiles, are attractive candidates for drug development [8,9].”
Anticancer Activity of the Marine-Derived Compound Bryostatin 1: Preclinical and Clinical Evaluation
Kowalczyk, T., Staszewski, M., Markowicz-Piasecka, M., Sikora, J., Amaro, C., Picot, L., & Sitarek, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167765 · Cited by 10
Ghaith, M. M., Almaimani, R. A., Ghareeb, A., Habibullah, M. M., Abdelkhalig, S. M., AlOmari, H., Albaqami, F. M. K., Albaldi, F. O., Alnumaani, S. A., Alshawwa, S. Z., et al. (2025) · RSC Advances · doi:10.1039/d5ra03971a · Cited by 9
EquilibraTor streamlines molecular dynamics simulations in a single execution
Cediel-Becerra, J. D. D., Silva, J. C. F., & Dias, R. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.11.034 · Cited by 7
Veluchamy, C., Nallakaruppan, N., Nachiappan, K., Sekaran, M., Vartak, R. B., Zambare, R. B., Panneerselvam, S., Chandrasekaran, R., Sharma, A., & Thiagarajan, K. (2025) · Frontiers in Marine Science · doi:10.3389/fmars.2025.1698327 · Cited by 13
(2023) · Microbial Bioactives · doi:10.25163/microbbioacts.617330 · Cited by 9
Hoang, T.-V., Alfarraj, S. A., & Alharbi, S. A. (2024) · Environmental Research · doi:10.1016/j.envres.2024.119026 · Cited by 9
Bhusare, N., Gade, A., & Kumar, M. S. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23732 · Cited by 10
Lee, J. H., Choi, B.-K., Kim, M., Shin, H. J., & Park, S. J. (2024) · Marine Drugs · doi:10.3390/md22120533 · Cited by 7
Tang, S., Wu, Z., Gao, M. Z., et al. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202200644 · Cited by 7
El‐Shorbagi, A., Chaudhary, S., Chaudhary, A., Agarwal, G., Tripathi, P. N., Dumoga, S., Aljarad, A. A., Mahmoud, F., Omer, E., Gupta, R. K., et al. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2398 · Cited by 7
Dhara, S., & Chakraborty, K. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113363 · Cited by 7
Niu, S., Huang, S., Wang, J., et al. (2022) · Natural Product Research · doi:10.1080/14786419.2022.2144299 · Cited by 7
“…extreme environments such as high pressure, high salinity, absence light, and low oxygen, etc, have been proved to be promising sources for structurally unique and biologically significant secondary metabolites (Daletos et al. 2018; Carroll et al. 2019; Khalifa et al. 2019; Carroll et al. 2022).”
BackgroundBarbosa, T. N., Silva, M. T. D. O., Sena-Lopes, Â., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285426 · Cited by 7
“Marine organisms, such as macroalgae, are good examples of such natural sources of active biomolecules that are useful in the development of novel drugs and related therapies [4].”
BackgroundExamination of Secondary Metabolite Biosynthesis in Apicomplexa
D’Ambrosio, H. K., Keeler, A. M., & Derbyshire, E. R. (2023) · ChemBioChem · doi:10.1002/cbic.202300263 · Cited by 7
Bosseboeuf, A., Baron, A., Duval, E., Gautier, A., Sourdaine, P., & Auvray, P. (2019) · Marine Drugs · doi:10.3390/md17120672 · Cited by 7
“Those peptides are usually derived from different organisms, mainly cyanobacterias, fungi, algae, sponges, tunicates, and mollusks [6,9,11,12].”
BackgroundCherbonolides M and N from a Formosan Soft Coral Sarcophyton cherbonnieri
Peng, C., Huang, T.-Y., Huang, C., et al. (2021) · Marine Drugs · doi:10.3390/md19050260 · Cited by 7
Synthesis and Cytotoxicity Evaluation of Spirocyclic Bromotyrosine Clavatadine C Analogs
Patel, P. A., Bruun, T., Ilina, P., et al. (2021) · Marine Drugs · doi:10.3390/md19070400 · Cited by 7
“Many marine-derived bioactive terpenes, alkaloids, macrolides, and other compounds isolated from aquatic fungi, cyanobacteria, algae, sponges, and tunicates have been found to exhibit anticancer activities [2,3].”
BackgroundMatulja, D., Grbčić, P., Bojanić, K., Popović, N. T., Čož‐Rakovac, R., Laclef, S., Šmuc, T., Jović, O., Marković, D., & Pavelić, S. K. (2021) · Molecules · doi:10.3390/molecules26195751 · Cited by 9
“Over recent decades, marine organisms were finally recognized as a new and rich source of bioactive natural products that might serve as scaffolds for the production of semisynthetic and synthetic derivatives to be turned into drugs and investigated in clinical trials [30].”
BackgroundLi, H., & Li, Z. (2022) · Bioengineering · doi:10.3390/bioengineering9110707 · Cited by 7
Loarer, A. L., Marcellin-Gros, R., Dufossé, L., Bignon, J. S., Frédérich, M., Ledoux, A., Queiroz, E. F., Wolfender, J., Gauvin‐Bialecki, A., & Fouillaud, M. (2023) · Microorganisms · doi:10.3390/microorganisms11030697 · Cited by 10
“Marine macroorganisms such as sponges are already known to produce metabolites with structural originality and remarkable biological activities [11,12].”
BackgroundDing, M., He, M., Li, D., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8354 · Cited by 6
Bonifácio, M., Martignago, C. C. S., Souza, D. C. S., Garcia-Motta, H., Souza-Silva, L. C., Soares‐Silva, B., Sousa, K. D. S. J., Rosso, A. P., Lago, J. H. G., Ribeiro, A. M., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c01171 · Cited by 6
Delivery mechanism of doxorubicin by PEG–DPPE micelles on membrane invasion by dynamic simulations
Zhao, L., Ren, M., Wang, Y., An, H., & Sun, F. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp05946k · Cited by 6
Liu, G., Zhang, S., Lin, R., Cao, X., & Yuan, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1307838 · Cited by 10
“Marine organisms have emerged as a recent research focus for the identi fi cation of novel compounds that hold potential in the prevention and treatment of cancer (7), and there is growing interest in exploiting the diverse and complex marine organisms for rational drug discovery (8).”
BackgroundNieddu, G., Obino, G., Ciampelli, C., Brunetti, A., Cubeddu, T., Manconi, R., Stocchino, G. A., Deiana, G. A., Formato, M., & Lepedda, A. J. (2024) · Marine Drugs · doi:10.3390/md22030139 · Cited by 8
“Among them, sulphated polysaccharides show interesting biological properties similar to those reported for mammalian glycosaminoglycans (GAGs) [21], including anticoagulant [20], antimalarial [22], antitumoral [23], and anti-HIV-1 [24], as well as anti-inflammatory [25], activities.”
BackgroundVirués-Segovia, J. R., Pinedo-Rivilla, C., Zorrilla, D., et al. (2024) · Frontiers in Marine Science · doi:10.3389/fmars.2024.1386175 · Cited by 6
Kavaliauskas, P., Grybaitė, B., Sapijanskaitė-Banevič, B., Anusevičius, K., Jonuškienė, I., Stankevičienė, R., Petraitienė, R., Petraitis, V., Grigalevičiūtė, R., Meškinytė, E., et al. (2024) · Molecules · doi:10.3390/molecules29133125 · Cited by 6
“Therefore, it is crucial to develop novel strategies targeting novel anticancer compounds for further preclinical evaluation [9–12].”
BackgroundMakhloufi, H., Pinon, A., Champavier, Y., Saliba, J., Millot, M., Fruitier‐Arnaudin, I., Liagre, B., Chemin, G., & Mambu, L. (2024) · Molecules · doi:10.3390/molecules29174117 · Cited by 12
“The progress in in biology, immunotherapy and the substantial improvements in modern drug design and manufacturing have made the discovery of a cure for cancer a feasible goal [6].”
Background
Metadata
- Authors
- Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., Chang, F.-R., Iwasaki, A., Suenaga, K., Alajlani, M., Göransson, U., & El-Seedi, H. R.
- Affiliations
- Karolinska University Hospital (SE)
- University of Kalamoon (SY)
- Cairo University (EG)
- Fujian Agriculture and Forestry University (CN)
- Quaid-i-Azam University (PK)
- Johannes Gutenberg University Mainz (DE)
- Kuwait University (KW)
- Department of Chemistry, Faculty of Science, University of Kuwait, 13060 Safat, Kuwait
- University of Karachi (PK)
- Kaohsiung Medical University (TW)
- Keio University (JP)
- Uppsala University (SE)
- Jiangsu University (CN)
- Corresponding author
- El-Seedi, Hesham R.
- ORCID
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2019-08-23
- Volume
- 17
- Issue
- 9
- Pages
- 491
- ISSN
- 1660-3397 (ISSN-L)
- PMC
- PMC6780632
- OpenAlex
- W2969876208
- Semantic Scholar
- fc04613de468c55e3c00acaa04bbf85967f96088
- Cited by
- 555
- References
- 235
- Citations by year
- 2026: 32 · 2025: 73 · 2024: 100 · 2023: 88 · 2022: 109 · 2021: 98 · 2020: 49 · 2019: 4
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Marine Drugs (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Uppsala University (Swedish Research links grant 2016-05885 (VR for the years 2017 - 2019))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
- Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Seaweed-derived Bioactive Compounds
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- marine natural products, anticancer agents, marine organisms, marine algae, marine bacteria, actinomycetes, marine fungi, marine sponges, soft coral, marine plants, apoptosis, cytotoxicity, cancer prevention, molecular mechanisms, bioactive metabolites, anticancer drug discovery
- MeSH terms
- Animals, Antineoplastic Agents, Biological Products, Clinical Trials as Topic, Disease Models, Animal, Humans, Neoplasms, Treatment Outcome, Aquatic Organisms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.